NCT00215709已完成1 期
A Pilot Study of Docetaxel on a Bi-Weekly Schedule in the Treatment of Elderly Men With Hormone-Refractory Prostate Cancer (HRPC)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- To determine the maximum tolerated dose (MTD) of docetaxel on a bi-weekly schedule in the treatment of elderly men with hormonal refractory prostate cancer (HRPC).
研究概览
简要总结
This pilot study is designed to determine the feasibility and safety of administering docetaxel at various dosing levels on a bi-weekly schedule in older men with hormone refractory prostate cancer.
详细描述
The information obtained from this trial will help determine the feasibility and safety of administering docetaxel at various dosing levels on a bi-weekly schedule in this patient population. If the data from this phase I trial are encouraging, a phase II trial will be conducted to further assess the efficacy of this dosing schedule.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •age ≥ 65 years;
- •histologically confirmed adenocarcinoma of the prostate;
- •metastatic disease;
- •unresponsive or refractory to hormonal therapy, as defined by at least 1 of the following criteria: progression of bidimensionally measurable disease; progression of evaluable but not measurable disease (bone scan); at least 2 consecutive rises in PSA at least 1 week apart;
- •patients must have serum testosterone levels < 50 ng/mL at time of study entry. For patients who are medically castrated, lutenizing hormone releasing hormone analog must continue to maintain testicular suppression;
- •prior nonsteroidal antiandrogens (flutamide, ketoconazole, bicalutamide, or nilutamide) allowed if disease progression occurred. No evidence of response after antiandrogen withdrawal within 4 weeks for patients treated with flutamide, ketoconazole, nilutamide and 6 weeks for patients treated with bicalutamide;
- •chemotherapy naïve;
- •full recovery from the effects of any prior surgery or radiation therapy. At least 4 weeks since any radiation therapy;
- •ECOG performance status 0-2;
- •adequate kidney, liver, and bone marrow functions;
- •signed study-specific informed consent form.
排除标准
- •Concurrent chemotherapy or immunotherapy;
- •Patients who have received an investigational drug within 4 weeks of registration;
- •Prior or concurrent malignancies (other than surgically treated carcinoma in situ of the cervix and squamous or basal cell carcinoma of the skin) within the preceding five years;
- •Serious medical or psychiatric illness which would prevent informed consent;
- •Life expectancy < 3 months;
- •Active uncontrolled bacterial, viral, or fungal infection until these conditions are corrected or controlled;
- •Known hypersensitivity to study drug or to other drugs formulated with polysorbate 80.
结局指标
主要结局
To determine the maximum tolerated dose (MTD) of docetaxel on a bi-weekly schedule in the treatment of elderly men with hormonal refractory prostate cancer (HRPC).
次要结局
- To determine the dose limiting toxicity effects and other toxic effects of this regimen
- To determine the activity of this regimen in terms of: Overall response rates; Pain scores and analgesic use; PSA response rates;
- To evaluate the feasibility of using a self-report geriatric assessment tool in this population
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric CancerGastric AdenocarcinomaNCT01567618Sixth Affiliated Hospital, Sun Yat-sen University39
已完成
2 期
A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained TherapyMalignant MelanomaNCT02223884Yonsei University30
终止
2 期
A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus CancersCancerNCT00177255University of Pittsburgh40
已完成
2 期
Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck CancerHead and Neck CancerNCT01645748Chonnam National University Hospital35
Unknown
2 期
Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGCStomach NeoplasmStage IVRecurrentNCT00510107Gachon University Gil Medical Center90